Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
We present the first reported work that explores the potential of radiomics to predict patients who are at risk for developing immunotherapy-induced pneumonitis. Despite promising results with immunotherapies, immune-related adverse events (irAEs) are challenging. Although less common, pneumonitis is a potentially fatal irAE. Thus, early detection is critical for improving treatment outcomes; an urgent need to identify biomarkers that predict patients at risk for pneumonitis exists. Radiomics, an emerging field, is the automated extraction of high fidelity, high-dimensional imaging features from standard medical images and allows for comprehensive visualization and characterization of the tissue of interest and corresponding microenvironment. In this pilot study, we sought to determine whether radiomics has the potential to predict development of pneumonitis. We performed radiomic analyses using baseline chest computed tomography images of patients who did (N = 2) and did not (N = 30) develop immunotherapy-induced pneumonitis. We extracted 1860 radiomic features in each patient. Maximum relevance and minimum redundancy feature selection method, anomaly detection algorithm, and leave-one-out cross-validation identified radiomic features that were significantly different and predicted subsequent immunotherapy-induced pneumonitis (accuracy, 100% [p = 0.0033]). This study suggests that radiomic features can classify and predict those patients at baseline who will subsequently develop immunotherapy-induced pneumonitis, further enabling risk-stratification that will ultimately lead to better treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a proof-of-concept study, 1860 radiomic features identified in chest CTs were obtained for each patient using first- and second-order texture analysis prior to therapy; skewness and angular variance of sum of squares (measure of dispersion) were higher in patients who later developed pneumonitis (Colen et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Colen et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Textural Features for Image Classification
Haralick, R. M., Shanmugam, K., & Dinstein, I. (1973) · IEEE Transactions on Systems, Man, and Cybernetics · doi:10.1109/tsmc.1973.4309314 · Cited by 22,886
Probability, Random Variables, and Stochastic Processes.
Abrahams, J., & Papoulis, A. (1984) · Journal of the American Statistical Association · doi:10.2307/2288754 · Cited by 16,226
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Due to its auto-immune mechanism, treatment-related pneumonitis is termed an Bevent of special interest [5, 6]^.”
Peng, H., Long, F., & Ding, C. (2005) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2005.159 · Cited by 10,544
Radiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Importantly, pneumonitisassociated deaths were reported in patients treated on nivolumab [9], pembrolizumab [10], and, combination of”
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citationDefining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Radiomics and deep learning in lung cancer
Avanzo, M., Stancanello, J., Pirrone, G., & Sartor, G. (2020) · Strahlentherapie und Onkologie · doi:10.1007/s00066-020-01625-9 · Cited by 263
Sollini, M., Antunovic, L., Chiti, A., & Kirienko, M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04372-x · Cited by 250
Elshafeey, N., Kotrotsou, A., Hassan, A., Elshafei, N., Hassan, I., Ahmed, S., Abrol, S., Agarwal, A., El Salek, K., Bergamaschi, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11007-0 · Cited by 147
Self-citation
Metadata
- Authors
- Colen, R. R., Fujii, T., Bilen, M. A., Kotrotsou, A., Abrol, S., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Giniebra-Camejo, D., Stephen, B., Subbiah, V., Sheshadri, A., Mendoza, T., Fu, S., Sharma, P., Meric-Bernstam, F., & Naing, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- Corresponding author
- Colen, Rivka R.
- Naing, Aung
- ORCID
- Venue
- Investigational New Drugs
- Published
- 2017-10-27
- Volume
- 36
- Issue
- 4
- Pages
- 601-607
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- PMC
- PMC5924418
- OpenAlex
- W2766233251
- Cited by
- 120
- References
- 34
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 9 · 2023: 16 · 2022: 15 · 2021: 22 · 2020: 22 · 2019: 8 · 2018: 8 · 2017: 1
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas (RP160150)
- John S. Dunn Sr. Distinguished Chair in Diagnostic Imaging Fund
- The University of Texas MD Anderson Cancer Center startup funding
- The University of Texas MD Anderson Cancer Center support grant (P30 CA016672)
- K23 Career Development Award, National Institutes of Health (K23AI117024)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Physical Sciences › Computer Science › Computer Vision and Pattern Recognition › Image Retrieval and Classification Techniques
- Keywords
- radiomics, immune-related adverse events, risk prediction, chest CT, radiomic feature selection, risk stratification, early detection
- MeSH terms
- Adult, Aged, Female, Humans, Immunologic Factors, Immunotherapy, Male, Middle Aged, Pilot Projects, Pneumonia, Risk, Biomarkers, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. https://app.cochat.ai/papers/10.1007/s10637-017-0524-2
- The paper
- Colen, R. R., Fujii, T., Bilen, M. A., Kotrotsou, A., Abrol, S., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Giniebra-Camejo, D., Stephen, B., Subbiah, V., Sheshadri, A., Mendoza, T., Fu, S., Sharma, P., Meric-Bernstam, F., & Naing, A. (2018). Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational New Drugs. https://doi.org/10.1007/s10637-017-0524-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.